The Latest Breaking News from Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The Dow Jones fell Wednesday following surprise jobs data and President Trump's speech to Congress. CrowdStrike plunged on earnings.

As the market turmoil deepens, here are two telltale indicators to track as investors adjust their lists of stocks to watch.

While Netflix and Meta stock fight to shake off market volatility, Eli Lilly and this biotech stock join them and others on IBD Leaderboard.

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

How To Buy And Sell Stocks: Use this IBD table to find stocks that are moving up and down in heavy volume on the stock market today.

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

Eli Lilly saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 94 the day before.

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.